Similar articles for PMID: 20496447

Year	Number of Results
1995	1
2005	1
2006	4
2007	7
2008	5
2009	7
2010	1
2011	3
2012	7
2013	3
2014	3
2015	1
2016	3
2017	1
2024	0

1

Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus: Final Report [Internet].

Norris SL, Lee NJ, Severance S, Thakurta S, Chan B. Norris SL, et al. Portland (OR): Oregon Health & Science University; 2008 Aug. Portland (OR): Oregon Health & Science University; 2008 Aug. PMID: 20496447 Free Books & Documents. Review.

2

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Herman GA, et al. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. doi: 10.1210/jc.2006-1009. Epub 2006 Aug 15. J Clin Endocrinol Metab. 2006. PMID: 16912128 Clinical Trial.

3

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ. Neumiller JJ. J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. J Am Pharm Assoc (2003). 2009. PMID: 19801361 Review.

4

Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.

Havale SH, Pal M. Havale SH, et al. Bioorg Med Chem. 2009 Mar 1;17(5):1783-802. doi: 10.1016/j.bmc.2009.01.061. Epub 2009 Jan 31. Bioorg Med Chem. 2009. PMID: 19217790 Review.

5

Newly approved and promising antidiabetic agents.

Combettes M, Kargar C. Combettes M, et al. Therapie. 2007 Jul-Aug;62(4):293-310. doi: 10.2515/therapie:2007054. Epub 2007 Nov 6. Therapie. 2007. PMID: 17983555 Review.

6

Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).

Gallwitz B. Gallwitz B. Drugs Today (Barc). 2007 Nov;43(11):801-14. doi: 10.1358/dot.2007.43.11.1157620. Drugs Today (Barc). 2007. PMID: 18174966 Review.

7

Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.

Gallwitz B. Gallwitz B. Drugs Today (Barc). 2007 Jan;43(1):13-25. doi: 10.1358/dot.2007.43.1.1043909. Drugs Today (Barc). 2007. PMID: 17315049 Review.

8

Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.

Siddiqui NI. Siddiqui NI. Mymensingh Med J. 2009 Jan;18(1):113-24. Mymensingh Med J. 2009. PMID: 19182763 Review.

9

Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.

Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA. Vardarli I, et al. Diabetes. 2014 Feb;63(2):663-74. doi: 10.2337/db13-0805. Epub 2013 Nov 1. Diabetes. 2014. PMID: 24186866 Clinical Trial.

10

A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.

Green BD, Gault VA, O'Harte FP, Flatt PR. Green BD, et al. Diabetes Obes Metab. 2005 Sep;7(5):595-604. doi: 10.1111/j.1463-1326.2004.00455.x. Diabetes Obes Metab. 2005. PMID: 16050953

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

42 results

Results by year